Edmonds Duncan Registered Investment Advisors LLC Sells 626 Shares of DexCom, Inc. (NASDAQ:DXCM)

Edmonds Duncan Registered Investment Advisors LLC lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 25.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,870 shares of the medical device company’s stock after selling 626 shares during the quarter. Edmonds Duncan Registered Investment Advisors LLC’s holdings in DexCom were worth $259,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of DXCM. CX Institutional purchased a new stake in shares of DexCom in the 4th quarter worth $286,000. Bank of New Hampshire purchased a new stake in DexCom in the first quarter worth about $1,508,000. abrdn plc raised its stake in shares of DexCom by 21.1% in the fourth quarter. abrdn plc now owns 380,535 shares of the medical device company’s stock worth $47,221,000 after buying an additional 66,348 shares during the period. Cerity Partners LLC lifted its position in shares of DexCom by 5,791.0% during the 4th quarter. Cerity Partners LLC now owns 463,973 shares of the medical device company’s stock valued at $57,574,000 after buying an additional 456,097 shares in the last quarter. Finally, Eagle Asset Management Inc. grew its stake in shares of DexCom by 21.5% during the 4th quarter. Eagle Asset Management Inc. now owns 1,756,216 shares of the medical device company’s stock valued at $217,929,000 after acquiring an additional 310,728 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Trading Down 0.4 %

Shares of DXCM stock traded down $0.46 during trading hours on Tuesday, reaching $111.71. 374,887 shares of the stock were exchanged, compared to its average volume of 2,937,115. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. The firm has a market capitalization of $44.42 billion, a price-to-earnings ratio of 72.29, a price-to-earnings-growth ratio of 2.77 and a beta of 1.16. DexCom, Inc. has a 12-month low of $74.75 and a 12-month high of $142.00. The company’s 50-day moving average price is $122.75 and its 200-day moving average price is $125.65.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. The company had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. As a group, equities analysts anticipate that DexCom, Inc. will post 1.78 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Kevin R. Sayer sold 49,633 shares of the firm’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the transaction, the chief executive officer now owns 283,893 shares in the company, valued at $39,262,401.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other DexCom news, EVP Sadie Stern sold 427 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $115.05, for a total value of $49,126.35. Following the completion of the transaction, the executive vice president now directly owns 75,877 shares in the company, valued at $8,729,648.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin R. Sayer sold 49,633 shares of the firm’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the completion of the sale, the chief executive officer now owns 283,893 shares in the company, valued at $39,262,401.90. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,735 shares of company stock worth $7,619,347. 0.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

DXCM has been the topic of several analyst reports. Citigroup lifted their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Canaccord Genuity Group raised their price target on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a report on Friday, April 26th. Redburn Atlantic began coverage on DexCom in a research note on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price objective for the company. UBS Group lifted their target price on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Finally, StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $140.33.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.